In non-small-cell lung cancer (NSCLC), Mikasa et al. found that NSCLC patients who received CAM treatment (200 mg b.i.d.)showed better conditions and prolonged survival times compared to those not treated with CAM due to reduced serum IL-6 levels after treatment [22, 23]. This evidence concerns the gene IL6 and non-small cell lung carcinoma.